Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients featuring Bright Uro
Glean™ Urodynamics System developed by Bright Uro based on foundational technology created at Cleveland Clinic; Device received FDA clearance earlier this year
Cleveland Clinic is the first to use the Glean™ Urodynamics System, the first wireless, catheter-free method of urodynamic monitoring following 510(k) clearance from the U.S. Food and Drug Administration in March.
Leveraging foundational technology generated from research conducted by Cleveland Clinic, Bright Uro created the Glean Urodynamics System which offers more comfortable, accurate testing and the ability to monitor bladder activity during normal daily activities.
Cleveland Clinic identified this critical unmet need in response to conventional urodynamic assessments (tests that demonstrate how well the bladder, sphincters, and urethra hold and release urine to determine the source of leaks or blockages), which have several limitations.
